- Forbes•1 hour ago
Second-quarter earnings season has been going for more than a week, and we’ve had a chance to hear from all four of the biggest companies in biotech as measured by sales, market valuation and clout. Here’s what they had to say in their business updates, along with some commentary from analysts
- Reuters•3 hours ago
Biotech returned to the good graces of investors this month and it may be the beginning of a revival for stocks in the industry. With one full trading day left in the month, the Nasdaq Biotechnology index has climbed 11 percent in July, on pace for its biggest monthly percentage gain in three years. Investors have sensed an opportunity to scoop up the stocks, analysts said.
Gilead Sciences Inc.NasdaqGS
After hours: 81.00-0.24 (-0.30%) as of 4:28 PM EDT
|Bid||81.20 x 500|
|Ask||81.23 x 500|
|52wk Range||77.92 - 120.37|
|Day's Range||80.62 - 81.98|
|Avg Vol (3m)||10,254,663|
As of 4:00 PM EDT. Market closed.